Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
-
-
Dynavax and CEPI announced $99 million in funding for CpG 1018 adjuvant manufacturing
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
-
Dynavax announced exercise of option to reserve additional CpG 1018 to produce 40 million doses of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option…
-
Pfizer and BioNTech publish preclinical data from investigational COVID-19 vaccine program in Nature
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
-
Clover and Dynavax announced planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
-
Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of phase 3 ENSEMBLE trial
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
-
Pfizer and BioNTech published data on COVID-19 vaccine-induced antibodiesﾒ ability to neutralize SARS-CoV-2 UK strain
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
-
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
-
Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
-
Vaxart announced publication that showed potential clinical and economic value of a Norovirus vaccine
On Jan. 27, 2021, Vaxart announced that health care economic findings published in the American Journal of Preventative…
-
OncoSec announced first subjects dosed in phase 1 trial of CORVax12, COVID-19 vaccine candidate
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
-
Moderna confirms discussions with US Government for additional 100 million doses of COVID-19 vaccine
On Jan. 27, 2021, Moderna confirmed that the Company is in discussion with the U.S. government to purchase…
-
In vitro studies demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with UK and South African Variants
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…
-
Vaxart announced additional preclinical COVID-19 oral vaccine data and publication
On Jan. 26, 2021, Vaxart announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a…
-
Moderna provided U.S. COVID-19 vaccine supply update
On Jan. 26, 2021, Moderna reported that 30.4 million doses have been supplied to the U.S. Government to…
-
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
-
Merck discontinued development of SARS-CoV-2/COVID-19 vaccine candidates
On Jan. 25, 2021, Merck announced that the company had discontinued development of its SARS-CoV-2/COVID-19 vaccine candidates, V590…
-
Medigen’s COVID-19 vaccine announced first participant dosed in phase 2 clinical trial in Taiwan
On Jan. 25, 2021, Medigen Vaccine Biologics and Dynavax Technologies announced that the first participant had been dosed…
-
Moderna COVID-19 vaccine retained neutralizing activity against emerging variants identified in UK and South Africa
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
-
Pfizer and BioNTech reached agreement with COVAX for advance purchase of vaccine to combat COVID-19
On Jan. 22, 2021, Pfizer and BioNTech announced an advance purchase agreement with COVAX for up to 40…
-
COVAX announced new agreement, plans for first deliveries
On Jan. 22, 2021, COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for…
-
Novavax and Government of Canada finalize advance purchase agreement for COVID-19 vaccine
On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to…
-
Zoetis Introducted Poulvac® Procerta™ HVT-IBD vaccine for infectious bursal disease
On Jan. 21, 2021, Zoetis announced it had as expanded its line of recombinant vector vaccines with the…
-
The US Department of Defense recommended adults 75 and older should seek COVID-19 vaccine
On Jan. 21, 2021, the U.S. Department of Defense (DOD) recommended that adults ages 75 and older should…
-
Moderna announced first participant dosed in phase 1/2 study of COVID-19 vaccine in Japan led by Takeda
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
-
ImmunityBio announced phase I trial of COVID-19 vaccine candidate in South Africa as new variants spread
On Jan. 19, 2021, ImmunityBio announced it had received authorization from the South Africa Health Products Regulatory Authority…
-
Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot program
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
-
Pfizer and BioNTech published results of study showing COVID-19 vaccine antibodies neutralized UK strain
On Jan. 19, 2021, Pfizer and BioNTech announced that results from an in vitro study that provided additional…
-
VBI Vaccines announced publication of results from phase 4 study of prophylactic 3-ntigen HBV in vaccine
On Jan. 15, 2021, VBI Vaccines announced that results from a Phase 4 study of VBIﾒs prophylactic 3-antigen…
-
UW researchers develop tool to equitably distribute limited vaccines
On Jan. 15, 2021, researchers at the University of Wisconsin School of Medicine and Public Health and UW…
